Arvinas Stock Price, News & Analysis (NASDAQ:ARVN) $21.97 -3.02 (-12.08%) (As of 11/30/2023 ET) Add Compare Share Share Today's Range$21.70▼$24.5450-Day Range$14.19▼$24.9952-Week Range$13.57▼$42.52Volume1.39 million shsAverage Volume472,877 shsMarket Capitalization$1.21 billionP/E RatioN/ADividend YieldN/APrice Target$51.77 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Arvinas MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.85 Rating ScoreUpside/Downside135.6% Upside$51.77 Price TargetShort InterestHealthy4.52% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.53Based on 7 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($5.26) to ($7.13) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.38 out of 5 starsMedical Sector253rd out of 949 stocksPharmaceutical Preparations Industry104th out of 437 stocks 4.4 Analyst's Opinion Consensus RatingArvinas has received a consensus rating of Moderate Buy. The company's average rating score is 2.85, and is based on 11 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $51.77, Arvinas has a forecasted upside of 135.6% from its current price of $21.97.Amount of Analyst CoverageArvinas has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 4.0 Short Interest Percentage of Shares Shorted4.52% of the float of Arvinas has been sold short.Short Interest Ratio / Days to CoverArvinas has a short interest ratio ("days to cover") of 4.4.Change versus previous monthShort interest in Arvinas has recently decreased by 18.01%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldArvinas does not currently pay a dividend.Dividend GrowthArvinas does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ARVN. Previous Next 2.5 News and Social Media Coverage News SentimentArvinas has a news sentiment score of 0.53. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.75 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Arvinas this week, compared to 2 articles on an average week.Search Interest7 people have searched for ARVN on MarketBeat in the last 30 days. This is an increase of 600% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Arvinas to their MarketBeat watchlist in the last 30 days. This is a decrease of -75% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Arvinas insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.55% of the stock of Arvinas is held by insiders.Percentage Held by Institutions86.33% of the stock of Arvinas is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Arvinas are expected to decrease in the coming year, from ($5.26) to ($7.13) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Arvinas is -3.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Arvinas is -3.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioArvinas has a P/B Ratio of 2.64. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Arvinas Stock (NASDAQ:ARVN)Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. Arvinas, Inc. was founded in 2013 and is based in New Haven, Connecticut.Read More ARVN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ARVN Stock News HeadlinesNovember 30, 2023 | markets.businessinsider.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Arvinas Holding Company (ARVN), UnitedHealth (UNH) and Argenx Se (ARGX)November 27, 2023 | msn.comWhy Arvinas (ARVN) Shares Are Seeing Blue SkiesNovember 30, 2023 | Tomorrow Investor (Ad)Why Microsoft Just Placed A Huge Bet On NuclearEven with aggressive expansion and acquisition of solar and wind farms, renewable energy isn’t anywhere close to providing the energy that Microsoft demands.November 27, 2023 | finance.yahoo.comArvinas Announces Oversubscribed $350 Million Private PlacementNovember 27, 2023 | finance.yahoo.comArvinas Announces Oversubscribed $350 Million Private PlacementNovember 24, 2023 | seekingalpha.comArvinas: Protein Degradation Pioneer Presents An Intriguing Speculative Buy OpportunityNovember 23, 2023 | americanbankingnews.comArvinas, Inc. (NASDAQ:ARVN) Given Consensus Recommendation of "Moderate Buy" by BrokeragesNovember 23, 2023 | americanbankingnews.comArvinas, Inc. (NASDAQ:ARVN) Receives Average Rating of "Moderate Buy" from AnalystsNovember 30, 2023 | Tomorrow Investor (Ad)Why Microsoft Just Placed A Huge Bet On NuclearEven with aggressive expansion and acquisition of solar and wind farms, renewable energy isn’t anywhere close to providing the energy that Microsoft demands.November 21, 2023 | americanbankingnews.comArvinas (NASDAQ:ARVN) Upgraded by Guggenheim to "Buy"November 20, 2023 | msn.comGuggenheim Upgrades Arvinas (ARVN)November 15, 2023 | finance.yahoo.comWall Street Analysts Predict a 165.07% Upside in Arvinas, Inc. (ARVN): Here's What You Should KnowNovember 15, 2023 | finance.yahoo.comWall Street Analysts Predict a 165.07% Upside in Arvinas, Inc. (ARVN): Here's What You Should KnowNovember 13, 2023 | finance.yahoo.comArvinas, Inc. (ARVN) Could Find a Support Soon, Here's Why You Should Buy the Stock NowNovember 12, 2023 | finance.yahoo.comArvinas, Inc.'s (NASDAQ:ARVN) latest 14% decline adds to one-year losses, institutional investors may consider drastic measuresNovember 8, 2023 | markets.businessinsider.comStrong Performance and Potential of ARV-766 Bolsters Buy Rating for Arvinas Holding CompanyNovember 7, 2023 | finance.yahoo.comArvinas Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateNovember 7, 2023 | finance.yahoo.comArvinas Inc (ARVN) Reports Q3 2023 Financial Results and Provides Corporate UpdateOctober 26, 2023 | markets.businessinsider.comHold Rating on Arvinas Holding Company: Prioritizing ARV-766 Over Bavdegalutamide and Its ImplicationsOctober 25, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Arvinas Holding Company (ARVN), Mereo Biopharma Group Plc (MREO) and Viking Therapeutics (VKTX)October 23, 2023 | msn.comWedbush Upgrades Arvinas (ARVN)October 23, 2023 | markets.businessinsider.comAnalyst Expectations for Arvinas's FutureOctober 18, 2023 | finance.yahoo.comArvinas Gives Back to Local Greater New Haven Community in Second Annual Impact DayOctober 15, 2023 | finance.yahoo.comArvinas and Pfizer Announce Upcoming Vepdegestrant (ARV-471) Poster Presentation at ESMO Congress 2023October 15, 2023 | finance.yahoo.comArvinas Announces Upcoming Bavdegalutamide Poster Presentation at ESMO Congress 2023September 8, 2023 | msn.comCantor Fitzgerald Reiterates Arvinas (ARVN) Overweight RecommendationSeptember 4, 2023 | seekingalpha.comArvinas' Potential In Treating ER+, HER2- Breast CancerSee More Headlines Receive ARVN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Arvinas and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/07/2023Today11/30/2023Fiscal Year End12/31/2023Next Earnings (Estimated)2/22/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ARVN CUSIPN/A CIK1655759 Webwww.arvinas.com Phone(203) 535-1456FaxN/AEmployees415Year FoundedN/APrice Target and Rating Average Stock Price Target$51.77 High Stock Price Target$95.00 Low Stock Price Target$20.00 Potential Upside/Downside+135.6%Consensus RatingModerate Buy Rating Score (0-4)2.85 Research Coverage13 Analysts Profitability EPS (Most Recent Fiscal Year)($5.53) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-282,500,000.00 Net Margins-185.09% Pretax Margin-175.38% Return on Equity-59.18% Return on Assets-25.76% Debt Debt-to-Equity RatioN/A Current Ratio3.26 Quick Ratio3.26 Sales & Book Value Annual Sales$131.40 million Price / Sales9.20 Cash FlowN/A Price / Cash FlowN/A Book Value$8.31 per share Price / Book2.64Miscellaneous Outstanding Shares55,030,000Free Float53,623,000Market Cap$1.21 billion OptionableNot Optionable Beta1.86 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesDr. John G. Houston Ph.D. (Age 63)Chairperson, CEO & President Comp: $1.08MDr. Ian Taylor Ph.D. (Age 60)Chief Scientific Officer Comp: $692kDr. Ronald A. Peck M.D. (Age 57)Chief Medical Officer Comp: $701.63kMr. David K. Loomis M.B.A. (Age 49)VP, Principal Accounting Officer & Chief Accounting Officer Mr. Jeff BoyleVice President of Investor RelationsDr. Randy Teel Ph.D. (Age 44)Senior Vice President of Corporate & Business Development Mr. Steve Weiss (Age 53)Senior VP & Chief Human Resources Officer Dr. John A. Grosso Ph.D. (Age 66)Senior Vice President of R&D Technical Operations Ms. Angela M. Cacace Ph.D. (Age 55)Senior Vice President of Neuroscience & Platform Biology Mr. John P. Northcott (Age 45)Chief Commercial Officer More ExecutivesKey CompetitorsRayzeBioNASDAQ:RYZBDisc MedicineNASDAQ:IRONAmneal PharmaceuticalsNYSE:AMRXMaravai LifeSciencesNASDAQ:MRVIAbCellera BiologicsNASDAQ:ABCLView All CompetitorsInsiders & InstitutionsDeutsche Bank AGSold 110,457 shares on 11/24/2023Ownership: 0.116%Jacobs Levy Equity Management Inc.Bought 29,240 shares on 11/17/2023Ownership: 0.218%Public Employees Retirement System of OhioSold 3,153 shares on 11/16/2023Ownership: 0.006%Wolverine Trading LLCSold 8,800 shares on 11/16/2023Ownership: 0.000%Sectoral Asset Management Inc.Bought 835 shares on 11/15/2023Ownership: 0.013%View All Insider TransactionsView All Institutional Transactions ARVN Stock Analysis - Frequently Asked Questions Should I buy or sell Arvinas stock right now? 13 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Arvinas in the last twelve months. There are currently 2 hold ratings and 11 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" ARVN shares. View ARVN analyst ratings or view top-rated stocks. What is Arvinas' stock price target for 2024? 13 Wall Street research analysts have issued 12 month target prices for Arvinas' shares. Their ARVN share price targets range from $20.00 to $95.00. On average, they anticipate the company's stock price to reach $51.77 in the next twelve months. This suggests a possible upside of 135.6% from the stock's current price. View analysts price targets for ARVN or view top-rated stocks among Wall Street analysts. How have ARVN shares performed in 2023? Arvinas' stock was trading at $34.21 at the beginning of 2023. Since then, ARVN shares have decreased by 35.8% and is now trading at $21.97. View the best growth stocks for 2023 here. Are investors shorting Arvinas? Arvinas saw a decrease in short interest in November. As of November 15th, there was short interest totaling 2,140,000 shares, a decrease of 18.0% from the October 31st total of 2,610,000 shares. Based on an average trading volume of 491,800 shares, the days-to-cover ratio is presently 4.4 days. Approximately 4.5% of the company's shares are sold short. View Arvinas' Short Interest. When is Arvinas' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, February 22nd 2024. View our ARVN earnings forecast. How were Arvinas' earnings last quarter? Arvinas, Inc. (NASDAQ:ARVN) posted its earnings results on Tuesday, November, 7th. The company reported ($1.18) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.58) by $0.40. The firm had revenue of $34.60 million for the quarter, compared to analysts' expectations of $39.58 million. Arvinas had a negative trailing twelve-month return on equity of 59.18% and a negative net margin of 185.09%. Arvinas's revenue for the quarter was up 14.2% on a year-over-year basis. During the same period last year, the company posted ($1.24) earnings per share. What ETFs hold Arvinas' stock? ETFs with the largest weight of Arvinas (NASDAQ:ARVN) stock in their portfolio include SPDR S&P Pharmaceuticals ETF (XPH), ALPS Medical Breakthroughs ETF (SBIO) and Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL).iShares U.S. Pharmaceuticals ETF (IHE). What other stocks do shareholders of Arvinas own? Based on aggregate information from My MarketBeat watchlists, some companies that other Arvinas investors own include Dynavax Technologies (DVAX), ImmunoGen (IMGN), Pfizer (PFE), CRISPR Therapeutics (CRSP), Energy Transfer (ET), OPKO Health (OPK), Advanced Micro Devices (AMD), Enphase Energy (ENPH), Fortress Biotech (FBIO) and Gilead Sciences (GILD). When did Arvinas IPO? (ARVN) raised $100 million in an IPO on Thursday, September 27th 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Goldman Sachs, Citigroup and Piper Jaffray served as the underwriters for the IPO. Who are Arvinas' major shareholders? Arvinas' stock is owned by a variety of retail and institutional investors. Top institutional investors include FMR LLC (8.85%), Avidity Partners Management LP (4.75%), JPMorgan Chase & Co. (3.61%), Northern Trust Corp (0.87%), Brown Advisory Inc. (0.81%) and Charles Schwab Investment Management Inc. (0.80%). Insiders that own company stock include Bradley Albert Margus, Briggs Morrison, Ian Taylor, John G Houston, John G Houston, Liam Ratcliffe, Ronald Peck, Sean A Cassidy and Timothy M Shannon. View institutional ownership trends. How do I buy shares of Arvinas? Shares of ARVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:ARVN) was last updated on 11/30/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arvinas, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.